摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[(2-Oxo-1,3,4,5-tetrahydropyrido[2,3-d][1,3]diazepin-8-yl)oxy]pentane-1-sulfonic acid

中文名称
——
中文别名
——
英文名称
5-[(2-Oxo-1,3,4,5-tetrahydropyrido[2,3-d][1,3]diazepin-8-yl)oxy]pentane-1-sulfonic acid
英文别名
5-[(2-oxo-1,3,4,5-tetrahydropyrido[2,3-d][1,3]diazepin-8-yl)oxy]pentane-1-sulfonic acid
5-[(2-Oxo-1,3,4,5-tetrahydropyrido[2,3-d][1,3]diazepin-8-yl)oxy]pentane-1-sulfonic acid化学式
CAS
——
化学式
C13H19N3O5S
mdl
——
分子量
329.37
InChiKey
KZYKLCVYIGDEPO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    22
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    126
  • 氢给体数:
    3
  • 氢受体数:
    6

文献信息

  • [EN] HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES ET LEURS PROCÉDÉS D'UTILISATION
    申请人:SUNOVION PHARMACEUTICALS INC
    公开号:WO2013169964A1
    公开(公告)日:2013-11-14
    Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.
    本文提供了杂环芳基化合物,其合成方法,包含这些化合物的药物组合物,以及它们的使用方法。在一个实施例中,本文提供的化合物可用于治疗、预防和/或管理各种疾病,如中枢神经系统疾病和神经系统疾病,包括但不限于精神病、精神分裂症、抑郁症、运动障碍和帕金森病。
  • HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    申请人:SUNOVION PHARMACEUTICALS INC.
    公开号:US20150072974A1
    公开(公告)日:2015-03-12
    Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.
    本文提供了杂环芳基化合物、其合成方法、包含这些化合物的药物组合物以及使用这些化合物的方法。在一个实施例中,本文提供的化合物可用于治疗、预防和/或管理各种疾病,例如中枢神经系统疾病和神经系统疾病,包括但不限于精神病、精神分裂症、抑郁症、运动障碍和帕金森病。
  • US9951088B2
    申请人:——
    公开号:US9951088B2
    公开(公告)日:2018-04-24
查看更多

同类化合物

氯吡卓醇 利喷西平 丙吡西平 N-[(4-苯基-2,3,4,5-四氢-1H-吡啶并[2,3-b][1,4]二氮杂卓-2-基)甲基]苯甲酰胺 N-[(4-苯基-2,3,4,5-四氢-1H-吡啶并[2,3-b][1,4]二氮杂卓-2-基)甲基]乙酰胺 9-叠氮基-11-乙基-6-甲基吡啶并[3,2-c][1,5]苯并二氮杂卓-5-酮 5-甲基-11-(甲磺酰)-5,11-二氢-6H-二吡啶并[3,2-b:2',3'-e][1,4]重氮基庚英-6-酮 5,11-二氢-4-甲基-6H-二吡啶并[3,2-b:2',3'-e][1,4]二氮杂卓-6-酮 4-苯基-2-氧代-5-(2-(4-甲基哌嗪-1-基)乙酰基)-1H-四氢吡啶并[2,3-b][1,4]二氮杂卓 4-苯基-1,3,4,5-四氢-2H-吡啶并[2,3-b][1,4]二氮杂卓-2-硫酮 4-(吗啉-4-基甲基)-1H-吡啶并[2,3-e][1,4]二氮杂卓-2,3,5(4H)-三酮 4,5-二氢-1H-吡啶并[2,3-E][1,4]重氮基庚英-3(2H)-酮 3-苯基-2-氧代-5-(2-(4-甲基哌嗪-1-基)乙酰基)-1H-四氢吡啶并[2,3-b][1,4]二氮杂卓 3-(乙酰氧基)-7-氯-5-(2-氯苯基)-1,3-二氢-2H-吡啶并[3,2-e]-1,4-二氮杂卓-2-酮 3,4,6,7-四氢-10-氯-1-苯基-8H-吡啶并[3,2,1-jk][1,4]苯并二氮杂卓-4,8-二酮 2-甲基-5-(2-吗啉-4-基乙基)-3,5-二氢-4H-吡啶并[2,3-b][1,4]重氮基庚英-4-酮盐酸 1OH-吡啶并(3,2-d)噻吩并(3,2-e)(1,4)-重氮基庚英-10-酮,4,9-二氢-4-((4-甲基-1-哌嗪基)乙酰基)-,盐酸盐 11-(N-甲基六氢烟酰基)-6,11-二氢-5H-吡啶并(2,3-b)-1,5-苯并二氮杂卓-5-酮 1-(5-甲基-3,4-二氢-2H-吡啶并[2,3-B] [1,4]二氮杂-1-基)乙酮 7,7a,8,9-tetrahydro-5-methyl-5H-pyrido<2,3-b>pyrrole<1,2-d><1,4>diazepin-6,10-dione 2-(3-butoxyphenyl)-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone (S,E)-N-methyl-3-(2-methyl-3-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-((3-methylbenzofuran-2-yl)methyl)acrylamide trifluoroacetic acid salt 4-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-d][1,3]diazepin-8-yloxy)butyl methanesulfonate 8-p-tolyl-6,7,9,14,15,16-hexahydroquinoxalino[1,2-a]pyrrolo[2,3-b][1,5]pyridodiazepin-6,7,15-trione 2-(2-furyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methylphenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-phenyl-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(2-thienyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-bromophenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-fluorophenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methoxyphenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methoxyphenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(4-fluorophenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(1-naphthyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 2-(2-furyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 2-(4-bromophenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(2-thienyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 8-chloro-1-methyl-1,2,3,4-tetrahydro-5H-pyrido[2,3-e][1,4]diazepin-5-one 2,3-dihydro-3-hydroxyimino-1-methyl-5-phenyl-1H-pyrido[4,3-e]-1,4-diazepine-2-one 7a,8,9,10-tetrahydro-5-methyldipyrido<2,3-b:1,2-d><1,4>diazepin-6,11(5H,7H)-dione 1-phenyl-2-{(Z)-(4RS)-4-(3-bromo-4,5-dimethoxyphenyl)-1,3,4,5-tetrahydro-2H-pyrido[2,3-b][1,4]diazepin-2-ylidene}-ethanone (+/-)-(R,R)-2-chloro-5-methyl-1,6a,7,8,9,10,10a,11-octahydrobenzo[b]pyrido[2,3-e][1,4]diazepin-4-one (E)-N-methyl-N-((3-methylbenzo[b]thiophen-2-yl)methyl)-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylamide 2-(3-Methoxyphenyl)-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone 8-Bromo-1,3-dihydro-4,9-dimethyl-2H-pyrido[2,3-b][1,4]diazepin-2-one 5,13-Dimethyl-7,11-diazoniatricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaene 5-(2-Morpholin-4-yl-ethyl)-2-phenyl-3,5-dihydro-pyrido[3,4-b][1,4]diazepin-4-one 4,9-dihydro-10H-pyrido[3,2-b]thieno[3,2-e][1,4]-diazepin-10-one (10S)-11-acetyl-10-(2,4-dichloro-phenyl)-7,7-dimethyl-5,6,7,8,10,11-hexahydro-3,5,11-triaza-dibenzo[a,d]cyclohepten-9-one (10R)-11-acetyl-10-(2,4-dichloro-phenyl)-7,7-dimethyl-5,6,7,8,10,11-hexahydro-3,5,11-triaza-dibenzo[a,d]cyclohepten-9-one